Larvol Delta - Artios-Reports-Randomized-Phase-2a-Study-of-Low-Dose-Alnodesertib-Plus-Gemcitabine-Achieves-Primary-Endpoint-in-PlatinumResistant-Ovarian-Cancer

alnodesertib (ART0380) - Artios Pharma

https://www.globenewswire.com/news-release/2026/03/02/3247293/0/en/Artios-Reports-Randomized-Phase-2a-Study-of-Low-Dose-Alnodesertib-Plus-Gemcitabine-Achieves-Primary-Endpoint-in-Platinum-Resistant-Ovarian-Cancer.html

Mar 2, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next